number 74191-85-8ATC code C02CA04PubChem 3157DrugBank APRD00474Chemical dataFormula C23H25N5O5Mol. mass 451.475 g/molPharmacokinetic dataBioavailability 65%Protein binding 98%Metabolism HepaticHalf life 22 hoursExcretion ?Therapeutic considerationsPregnancy cat. ?Legal status ? search doxazosin onlyRoutes.

high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained search doxazosin form of doxazosin, to be marketed as Cardura® XL.It is an alpha search doxazosin used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an search doxazosin search doxazosin search doxazosin to treat high blood pressure and benign prostatic hyperplasia.On February search doxazosin 2005, the US FDA approved search doxazosin sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha-1 adrenergic receptor blocker which inhibits the binding of norepinephrine to alpha receptors in the autonomic nervous system. The primary effect of search doxazosin blockage is relaxed vascular smooth muscle tone (vasodilation), which decreases.

C02CA04PubChem 3157DrugBank APRD00474Chemical dataFormula C23H25N5O5Mol. mass 451.475.